Causeway Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$3.09M
- Investors
-
8
Causeway Therapeutics General Information
Description
Developer of novel microRNA therapies designed to treat common musculoskeletal diseases. The company develops therapies that are based on identifying the molecular mechanism that causes damaged tendons to develop tendinopathy caused by loss of microRNA and controls the repair process by their pharmaceutical product that mimics this natural microRNA and cures them, enabling patients to reduce the pain of damaged and weakened tendons in a faster and advanced way.
Contact Information
Website
www.causewaytx.comCorporate Office
- Imaging Centre of Excellence Building
- Queen Elizabeth University Hospital
- Glasgow G51 4TF
- Scotland, United Kingdom
Corporate Office
- Imaging Centre of Excellence Building
- Queen Elizabeth University Hospital
- Glasgow G51 4TF
- Scotland, United Kingdom
Causeway Therapeutics Timeline
Causeway Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 25-Jul-2025 | $3.09M | Completed | Generating Revenue | ||
| 7. Later Stage VC | 27-Feb-2023 | Completed | Clinical Trials - Phase 2 | |||
| 6. Grant | 01-Jun-2020 | Completed | Clinical Trials - Phase 1 | |||
| 5. Grant | 01-Feb-2019 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC | 19-Jun-2018 | Completed | Clinical Trials - Phase 1 | |||
| 3. Grant | 31-May-2018 | Completed | Clinical Trials - Phase 1 | |||
| 2. Seed Round | 03-Aug-2017 | $1.3M | $1.3M | Completed | Clinical Trials - Phase 1 | |
| 1. University Spin-Out | 20-Oct-2015 | Completed | Startup |
Causeway Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferred Series 2 | ||||||||
| Preferred Series 2 | ||||||||
| Preferred Series 2 | ||||||||
| Preferred Series 2 | ||||||||
| Preferrence | 500,000 | $0.000136 | $2.71 | $2.71 | 1x | $2.71 | 10.43% | |
| Preferrence | 640,000 | $0.000136 | $2.12 | $2.12 | 1x | $2.12 | 13.35% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Causeway Therapeutics Patents
Causeway Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023445724-A1 | Microrna-29 compounds, compositions and uses in therapy, and methods for evaluating tendinopathic lesions | Pending | 28-Apr-2023 | ||
| US-20240360446-A1 | Microrna-29 compounds, compositions and uses in therapy, and methods for evaluating tendinopathic lesions | Pending | 28-Apr-2023 | ||
| WO-2024223065-A1 | Microrna-29 compounds, compositions and uses in therapy, and methods for evaluating tendinopathic lesions | Inactive | 28-Apr-2023 | ||
| AU-2021365394-A1 | Microrna-29 compounds, compositions and uses in therapy | Pending | 23-Oct-2020 | ||
| AU-2021365394-A9 | Microrna-29 compounds, compositions and uses in therapy | Pending | 23-Oct-2020 |
Causeway Therapeutics Signals
Causeway Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| GU Holdings | Holding Company | Minority | ||
| Rahn+Bodmer | Asset Manager | Minority | ||
| Angel (individual) | Minority | |||
| University of Glasgow Endowment | Limited Partner | Minority | ||
| Innovate UK | Government |
Causeway Therapeutics FAQs
-
When was Causeway Therapeutics founded?
Causeway Therapeutics was founded in 2015.
-
Where is Causeway Therapeutics headquartered?
Causeway Therapeutics is headquartered in Glasgow, United Kingdom.
-
What is the size of Causeway Therapeutics?
Causeway Therapeutics has 7 total employees.
-
What industry is Causeway Therapeutics in?
Causeway Therapeutics’s primary industry is Drug Discovery.
-
Is Causeway Therapeutics a private or public company?
Causeway Therapeutics is a Private company.
-
What is the current valuation of Causeway Therapeutics?
The current valuation of Causeway Therapeutics is .
-
What is Causeway Therapeutics’s current revenue?
The current revenue for Causeway Therapeutics is .
-
How much funding has Causeway Therapeutics raised over time?
Causeway Therapeutics has raised $23M.
-
Who are Causeway Therapeutics’s investors?
GU Holdings, Rahn+Bodmer, , University of Glasgow Endowment, and Innovate UK are 5 of 8 investors who have invested in Causeway Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process